# ACHILLES THERAPEUTICS PLC (ACHL)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/ACHL/

- Reporting holders: 3
- Reported value: $98.9K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Trium Capital LLP](https://holderbook.com/funds/1963860-trium-capital-llp/) | $91.0K | 61,506 | 0.1% | 2 |
| [RHUMBLINE ADVISERS](https://holderbook.com/funds/1115418-rhumbline-advisers/) | $6.6K | 4,480 | 0.0% | 10 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $1.2K | 806 | 0.0% | 6 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 3 | $98.9K |
| Q1 2026 | 3 | $53.3K |
| Q4 2025 | 2 | $7.8K |
| Q3 2025 | 2 | $7.8K |
| Q2 2025 | 2 | $7.8K |
| Q1 2025 | 5 | $80.2K |
| Q4 2024 | 20 | $15.1M |
| Q3 2024 | 21 | $13.5M |
| Q2 2024 | 25 | $9.0M |
| Q1 2024 | 31 | $29.4M |
| Q4 2023 | 19 | $19.4M |
| Q3 2023 | 16 | $7.8M |